Guía de Linfoma de GELTAMO vs. Trialing Utilizzo e statistiche

This mobile app with Interactive Guides in Lymphoma has been developed by the Spanish Research Group specialized in Lymphomas (GELTAMO). These interactive guides have been prepared and reviewed by leading lymphoma experts and are grounded in evidence-based medicine findings, providing a comprehensive set of recommendations for medical professionals to help patients with the best care options. This app must be able to be used in mobile devices by medical professionals in geographic areas without Internet connection and medical centers isolated installations without Internet connection such us nuclear medicine, radiotherapy rooms among others.
  • App Store di Apple
  • Gratis
  • Settore Medico

Classifica degli store

- -

Trialing is a platform that helps doctors easily find the most suitable clinical trial for their patients and establish direct contact with the principal investigator. No delays or bureaucracy. We work with reviewed, organized, and categorized data. At Trialing, we don't settle for just showing the features of clinical trials; we go into detail. Thanks to our network of healthcare professionals, we know precisely which hospitals are recruiting. This way, you can choose the most appropriate hospital to refer your patient to. At Trialing, we offer the opportunity to contact the destination center directly: no intermediaries and no delays.
  • App Store di Apple
  • Gratis
  • Settore Medico

Classifica degli store

- -

Guía de Linfoma de GELTAMORanking a confronto con Trialing

Confronta la tendenza di classifica Guía de Linfoma de GELTAMO nei ultimi 28 giorni rispetto a Trialing

Rank

Nessun dato disponibile

Classifica Guía de Linfoma de GELTAMO vs. Trialing per paese a confronto

Confronta la tendenza di classifica Guía de Linfoma de GELTAMO nei ultimi 28 giorni rispetto a Trialing

Nessun dato da visualizzare

Fai confronti con qualsiasi sito con la nostra prova gratuita

Inizia
Guía de Linfoma de GELTAMO VS.
Trialing

13icembre d, 2024